Skip to Main Content
Welcome to the Scientist.com Marketplace

Go to Main Navigation

37992

BSP-16

Cayman Chemical

Thumbnail image

DETAILS

  • Inchi: InChI=1S/C16H18O5Se/c1-4-9(16(18)19)5-11(17)15-7-10-6-12(20-2)13(21-3)8-14(10)22-15/h6-9H,4-5H2,1-3H3,(H,18,19)/t9-/m1/s1
  • Purity: ≥98%
  • Raptas: Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Cancer|Immunology||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Autoimmunity||Research Area|Immunology & Inflammation|Innate Immunity|Pattern Recognition||Research Area|Immunology & Inflammation|Innate Immunity|STING||Research Area|Infectious Disease
  • Smiles: O=C(C[C@@H](CC)C(O)=O)C1=CC2=CC(OC)=C(OC)C=C2[Se]1
  • Inchikey: BWQHPFYQJHFPHN-SECBINFHSA-N
  • Cas Number: 2727249-47-8
  • Formulation: A solid
  • Storage Temp: -20
  • Shipping Temp: -20
  • Formula Markup: C16H18O5Se
  • Formula Weight: 369.3
  • Shelf Life Days: 1095

DESCRIPTION

A STING agonist; binds to STING (Kd = 23 µM); induces the production of IFN-β, IL-6, and CXCL10 in THP-1 cells at 10, 25, and 50 µM; induces phosphorylation of IRF3 and TBK1 in THP-1 cells at 50 µM; reduces tumor volume in an MC-38 murine carcinoma model and induces tumor regression in a CT26 murine colorectal carcinoma model at 15 and 30 mg/kg; prevents tumor cell re-challenge-induced tumor formation in a CT26 murine carcinoma model; reduces tumor volume and increases the number of activated CD8+ T cells and NK cells in a 4T1 murine mammary carcinoma model at 20 mg/kg